Aldometanib | Aldolase inhibitor

Available Options

Size:PriceQuantity 
5 mg$65.00
25 mg$225.00
Request Quote / Bulk / Custom Size
Product Inquiry

Aldometanib (2904601-67-6) inhibits (IC50 = 50 µM) aldolase by blocking its binding with fructose-1,6-bisphosphate (FBP).1 It activates lysosomal AMPK and mimics a cellular state of glucose starvation. Aldometanib alleviated fatty liver and nonalcoholic steatohepatitis in mice and extended lifespan. It mitigated inflammation and oxidative stress damage in LPS-treated lung fibroblasts and also inhibited NLRP3-mediated pyroptosis.2  Aldometanib inhibited hepatocellular carcinoma in mice in an AMPK-dependent manner.3 It rebalanced the tumor microenvironment allowing cytotoxic CD8+ T cells to infiltrate tumor cells.

References/Citations:

  1. Zhang et al. (2022), The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK; Nat. Metab., 4 1369
  2. Shao et al. (2025), Aldometanib mitigates LPS-induced lung fobroblasts injury through the activation of AMPK-mediated signaling pathways; Toxicon, 265 108489
  3. Hu et al. (2025), Glucose starvation mimetic aldometanib removes immune barriers permitting mice with hepatocellular carcinoma to live to normal ages; Cell Res., 35 934
2904601-67-6, aldolase inhibitor, aldometanib, Aldometanib supplier
Alternate Name:
LXY-05-029

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Aldometanib (2904601-67-6) inhibits (IC50 = 50 µM) aldolase by blocking its binding with fructose-1,6-bisphosphate (FBP).1 It activates lysosomal AMPK and mimics a cellular state of glucose starvation. Aldometanib alleviated fatty liver and nonalcoholic steatohepatitis in mice and extended lifespan. It mitigated inflammation and oxidative stress damage in LPS-treated lung fibroblasts and also inhibited NLRP3-mediated pyroptosis.2  Aldometanib inhibited hepatocellular carcinoma in mice in an AMPK-dependent manner.3 It rebalanced the tumor microenvironment allowing cytotoxic CD8+ T cells to infiltrate tumor cells.

References/Citations:

  1. Zhang et al. (2022), The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK; Nat. Metab., 4 1369
  2. Shao et al. (2025), Aldometanib mitigates LPS-induced lung fobroblasts injury through the activation of AMPK-mediated signaling pathways; Toxicon, 265 108489
  3. Hu et al. (2025), Glucose starvation mimetic aldometanib removes immune barriers permitting mice with hepatocellular carcinoma to live to normal ages; Cell Res., 35 934